Short answer

Spero Therapeutics Inc (SPRO) filed its Q1 2019 10-Q quarterly report on May 9, 2019 for the quarter ended Mar 31, 2019.

Spero Therapeutics Inc Q1 2019 10-Q analysis

AI summary of MD&A and risk factor updates

Revenue $7.718M, up $6.565M YoY, driven by $3.807M collaboration revenue and $3.911M grant revenue
Net loss $5.072M vs $10.644M YoY, operating loss $5.696M vs $10.816M
SPR994 R&D $3.708M vs $2.352M, while Potentiator Platform R&D $1.236M vs $3.441M
Cash, equivalents and marketable securities $106.4M; operating cash outflow $10.924M
Funding expected into second half of 2020, but additional capital needed for full development and commercialization

Newly added risk: Everest Medicines collaboration could terminate, jeopardizing SPR206 development rights in Greater China, South Korea and Southeast Asia
Most materially updated risk: BARDA funding supports operations into the second half of 2020, but options remain subject to agency exercise
Regulatory compliance risk: Government contracts permit audits, funding termination, False Claims Act liability and intellectual-property restrictions
Operational risk: Reliance on a small number of third-party manufacturers without long-term agreements creates potential supply delays
Financial risk: $15.7 million BARDA base-period funding is subject to two options and government appropriations beyond committed amounts

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.